Food News and Research

RSS

Durata completes target enrollment in dalbavancin Phase 3 trials for abSSSI

Durata Therapeutics today announced that it has completed its target enrollment for DISCOVER 1 ("Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response"), one of two ongoing, global, Phase 3 clinical trials of Durata's lead product candidate, dalbavancin, under investigation for the treatment of acute bacterial skin and skin structure infections (abSSSI).

7 Sep 2012

Nutritional benefits of organic foods questioned

Strong evidence to support the supposed nutritional benefits of eating organic over conventional foods is lacking in the scientific literature, show results from a systematic review.

6 Sep 2012

Constipation drug may bring US patients relief

The US Food and Drug Administration has approved linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation in adults.

6 Sep 2012

Night eating syndrome increased in schizophrenia patients

The prevalence of night eating syndrome is significantly increased among patients with schizophrenia or schizoaffective disorder who are obese, results from a US study suggest.

6 Sep 2012

Reduced NF-κB expression linκed to postradiation oral mucosa vulnerability

The fragility of oral mucosa after radiotherapy for oral squamous cell carcinoma may be due to the inhibition of the DNA transcriptor protein nuclear factor κappa-light-chain-enhancer of activated B cells, show study findings.

6 Sep 2012

Hopes dashed for ginkgo biloba in Alzheimer’s disease

The GuidAge trial of ginkgo biloba extract in people with evidence of memory problems confirms that the treatment does not reduce their risk for progression to Alzheimer’s disease.

6 Sep 2012

Alzheimer’s disease is not prevented by ginkgo biloba

Ginkgo biloba extract does not significantly reduce the likelihood of diagnosis of Alzheimer’s disease in older people, according to the results of the largest ever Alzheimer’s prevention study in Europe, published in The Lancet Neurology.

6 Sep 2012

Omeros files OMS824 IND with FDA to initiate clinical trials for cognitive disorders

Omeros Corporation today announced that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to initiate clinical trials evaluating OMS824, the Company's lead compound from its phosphodiesterase 10 (PDE10) program for schizophrenia and other cognitive disorders.

6 Sep 2012

Harvard experts create biocompatible hydrogel

A team of experts in mechanics, materials science, and tissue engineering at Harvard have created an extremely stretchy and tough gel that may pave the way to replacing damaged cartilage in human joints.

6 Sep 2012

Study sheds light on why women gain fat following menopause

A high-fat diet triggers chemical reactions in female mice that could explain why women are more likely than men to gain fat in the abdomen after eating excess saturated fat, new research suggests. The study also sheds light on why women gain fat following menopause.

6 Sep 2012

UC Davis plans to open West Coast Metabolomics Center

With a $9.3 million startup grant from the National Institutes of Health, the University of California, Davis, has announced plans to open the West Coast Metabolomics Center, a high-tech consortium of research and service laboratories that will help scientists better understand and develop more effective treatments for complex diseases like diabetes, cancer and atherosclerosis.

6 Sep 2012

Nearly one-third of under-five children malnourished in southern Afghanistan, survey shows

Approximately one-third of children under the age of five in southern Afghanistan, about one million, have acute malnutrition, "with a level of deprivation similar to that found in famine zones, a government survey has found, despite the hundreds of millions of dollars in foreign aid that has been poured into the region," the Guardian reports.

6 Sep 2012

FDA continues review of Salix’s Crofelemer new drug application

Napo Pharmaceuticals, Inc. was informed today that the Food and Drug Administration is continuing its review of the new drug application seeking approval of crofelemer for the treatment of chronic diarrhea in people living with HIV/AIDS on anti-retroviral therapy.

6 Sep 2012

Biologic therapies do not increase risk of cancer in patients with rheumatoid arthritis

Biologic therapies developed in the last decade for rheumatoid arthritis are not associated with an increased risk of cancer when compared with traditional treatments for the condition, according to new research from The University of Texas MD Anderson Cancer Center.

6 Sep 2012

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Pfizer Inc. announced today the U.S. Food and Drug Administration (FDA) has approved BOSULIF (bosutinib), an Abl and Src kinase inhibitor, for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.

6 Sep 2012

Viewpoints: Anti-abortion Democrats praise health law; A defense of the Medicare cost-cutting board

The big question heading into the Democratic Convention is just how forcefully the party will defend the Affordable Care Act, which the president fought to pass and then declined to sell. On Tuesday, an unusually vocal endorsement of the law came from an unlikely source: Anti-abortion Democrats.

6 Sep 2012

UEA, IFR to study protective effects of broccoli consumption against prostate cancer

The Prostate Cancer Foundation is providing $1M of funding to the Institute of Food Research and the University of East Anglia (UEA) to study the protective effects of broccoli consumption against prostate cancer.

6 Sep 2012

Janssen receives FDA Priority Review for bedaquiline NDA to treat MDR-TB

Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for bedaquiline (TMC207) to treat pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults as part of combination therapy.

6 Sep 2012

Exposure to household chemical may raise cardiac risk

Exposure to perfluorooctanoic acid may be associated with cardiovascular disease and peripheral arterial disease, say researchers.

5 Sep 2012

Educational program for parents helps reduce pressure on children to eat

An educational program for parents helps to reduce pressure on children to eat—which may reduce the child's risk of obesity, reports a study in the September Journal of Developmental & Behavioral Pediatrics, the official journal of the Society for Developmental and Behavioral Pediatrics.

5 Sep 2012